Bayer calls for deregulation as healthcare reform cost it €300 million
This article was originally published in Scrip
Executive Summary
Instead of putting the squeeze on innovation, Bayer wants to see more deregulation and reforms that stimulate competition, the firm told Scrip. Global healthcare reform cost the firm €300 million in 2011, with the biggest impact coming from the US and Germany, it said.
You may also be interested in...
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.
Germany Courts Clinical Trials With Regulator Reshuffle & New Federal Ethics Committee
Plans to rejig two regulators’ roles and streamline the ethics committee system have drawn some criticism.